ニュース

Biointron, a leading contract research organization (CRO) specializing in antibody discovery, optimization, and expression services, is proud to announce more than 2,500 biotech and pharmaceutical customers worldwide. This achievement underscores our trusted role in accelerating antibody research an

Introducing a new High-throughput Fully Humanized Antibody Discovery Platform with Biointron AbDrop & Cyagen HUGO-Ab! This novel approach combines microfluidic technology for single B cell antibody discovery and fully human antibody mice for a safer and more efficient approach for fully human antibody discovery​, ready in as quickly as 3 months.

Biointron is proud to share that we have received the 2024 Scientist.com Supplier Performance Recognition Award, for our dedication to providing high-quality drug discovery research services on this industry-renowned R&D sourcing platform.

In March 2024, Cyagen and Biointron officially signed off on their strategic partnership, forging an alliance in antibody drug development. This partnership aims to fully leverage the strengths of Cyagen's HUGO-Ab™ fully humanized mouse antibody discovery platform and Biointron&#

Biointron is proud to announce a strategic partnership with FatiAbGen, a leading biotechnology firm focused on antibody-based therapeutics. As the newly appointed Korean distributor for Biointron, FatiAbGen will be at the forefront of delivering Biointron’s products to the Korean market.

Celebrate International Women's Day with Biointron's female workforce!

Biointron is excited to announce our newly launched CHOK1-Fut8KO expression platform for afucosylated antibodies.

On March 21st, Biointron Biological Shanghai R&D Center welcomed AstraZeneca delegations Mark Cobbold, Margie Li, Hao Huang, and Yingjie Wu for an on-site visit.

Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies.